Target intelligence / Profile preview

Gastrointestinal mucosal membrane

Molecular classification
Other (not a single molecule, but a tissue/membrane structure), Epithelial barrier, Mucus layer (composition includes secreted proteins, mainly mucins)
01

Overview

The gastrointestinal mucosal membrane is the innermost lining of the GI tract, composed primarily of epithelial cells, an underlying lamina propria, and a thin layer of smooth muscle called the muscularis mucosae[2]. It is covered by a mucus layer mainly secreted by goblet cells, consisting of mucins such as MUC2, MUC5AC, MUC5B, and MUC6[3][4]. This structure serves as a crucial physical and biochemical barrier, facilitating lubricated passage of food, protection from pathogens and acid, nutrient absorption, and immune surveillance[2][3][4]. Dysfunction or injury to the mucosal membrane underlies many GI diseases, including inflammatory, neoplastic, and infectious processes[3][4].

Other names
Gastrointestinal mucosaGI mucosaGI mucosal barrierIntestinal mucosaGastric mucosa
02

Mechanism of action

Drugs affecting the gastrointestinal mucosal membrane can act through various mechanisms including enhancement of mucus secretion or barrier function (e.g., sucralfate, misoprostol), inhibition of acid secretion (e.g., proton pump inhibitors), immunosuppression or anti-inflammatory effects (e.g., corticosteroids, mesalamine), or antibiotic/antimicrobial action on microbiota.

03

Biological functions

Protection against mechanical and chemical injuryBarrier to pathogens and toxinsLubrication of luminal contentsAbsorption of nutrients (mainly in intestinal regions)Secretion of mucus, enzymes, and immune mediatorsHosting a significant proportion of gut immune defense
04

Disease associations

Inflammation (e.g., inflammatory bowel disease, ulcerative colitis)Infection (e.g., enteric pathogens, amoebiasis)Cancer (e.g., colorectal cancer, gastric cancer)Other (e.g., mucosal barrier dysfunction in diabetes, liver disease)
05

Safety considerations

Mucosal injury or ulceration (NSAIDs, infections)Increased intestinal permeability leading to infection and inflammationMicrobial dysbiosis and subsequent chronic diseaseDelayed mucosal healing in high-risk patients
06

Interacting drugs

Proton pump inhibitors

6 more in the full profile.

07

Biomarkers

Fecal calprotectinSerum/colonic mucin expression (MUC2, MUC5AC, MUC6)Fecal occult bloodEndoscopic mucosal appearance

Beyond the preview

Go deeper on Gastrointestinal mucosal membrane.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Gastrointestinal mucosal membrane.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call